Post-transplant recurrent hepatitis B viral liver disease: Viral-burden, steatoviral, and fibroviral hepatitis B

M. J. Phillips*, R. Cameron, M. A. Flowers, L. M. Blendis, P. D. Greig, I. Wanless, M. Sherman, R. Superina, B. Langer, G. A. Levy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


Recurrence of hepatitis is a well-documented complication of hepatitis B liver disease, post-transplantation. It is well established also that the earliest hepatocellular change is the appearance of hepatitis B viral (HBV) markers and that the disease is rapidly progressive. In this article on 17 liver transplants in 16 HBV positive patients with long-term follow-ups (100- 1234 days), the distinctive pathologic features of this disease are emphasized: the extreme viral load, the steatosis, and/or fibrosis. An attempt to quantitate the magnitude of the viral burden was made and the result was a staggering figure. In one patient, an estimated 10 18 HBV core particles were present in the liver. One of two patterns of progression were noted. In four patients in addition to the massive nuclear hepatitis B core antigen (HBcAg) and cytoplasmic hepatitis B surface antigen (HBsAg) positivity, superimposed hepatitic changes led to diffuse hepatic fibrosis (fibroviral hepatitis B); and in another six patients, extraordinary hepatocellular viral marker positivity and steatosis were the hallmarks (steatoviral hepatitis B). Steatosis is not usually considered a feature of HBV liver pathology. These results suggest that more than one type of posttransfusion recurrent hepatitis B liver disease exists pathologically.

Original languageEnglish (US)
Pages (from-to)1295-1308
Number of pages14
JournalAmerican Journal of Pathology
Issue number6
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Post-transplant recurrent hepatitis B viral liver disease: Viral-burden, steatoviral, and fibroviral hepatitis B'. Together they form a unique fingerprint.

Cite this